Bibliographical noteFunding Information:
This study was funded by the National Institutes of Health (NIH) (grant nos. T32 AI007635, U19 AI070503-01, U19 AI104317, and P01 HL070831), and the project was supported by the Clinical and Translational Science Award program, through the NIH National Center for Advancing Translational Sciences (grant no. UL1TR000427).
Disclosure of potential conflict of interest: J. E. Gern's institution received a grant from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) for this work; he personally received consultancy fees from Janssen, Regenoron, and PReP BIosciences; travel expenses from Boehringer Ingelheim; and has a research agreement (via the University of Wisconsin) with MedImmune LLC involving exchange of scientific materials. R. Gangnon's, M. D. Evans', and Y. A. Bochkov's institutions received a grant from the NIH for this work. D. J. Jackson's institution received a grant from the NHLBI for this work; he personally received fees from Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Commense for other works. R. F. Lemanske's institution received a grant and he personally received payment for writing the manuscript and provisions for administrative support from the NHLBI for this work; he personally received board membership from the American Academy of Allergy, Asthma, and Immunology; is employed by the University of Wisconsin School of Medicine and Public Health; received payment for lectures from the Asthma and Allergy Foundation of America-Alaska Chapter, the Egyptian Allergy Society, and Louisiana State University; and royalties from Elsevier and UpToDate; his institution received grants from the NHLBI and Pharmaxis for other works. The rest of the authors declare that they have no relevant conflicts of interest. Letter to the Editor